LLY

Eli Lilly and Company LLY logo

NYSE Healthcare

$910.91

+26.39 (+2.98%)

Updated: 3/31/2026, 4:00:01 PM

Open

$893.49

High

$923.98

Low

$887.20

Prev Close

$886.63

Volume

1.06M

Price History

Why Is LLY ▲ Up Today?

+2.98%

Full AI analysis generates after market close. Showing live price data.

Mar 31 ▲ +3.0% LLY Up Nearly 3% on Sleep Medicine Expansion

Mar 30 ▲ +0.8% LLY Up Slightly on AI Drug Discovery Deal

Mar 27 ▼ -2.3% Eli Lilly (LLY) Down 2.29% Amidst Mixed News and Sector Weakness

Mar 26 ▼ -1.9% LLY Declines Amidst Sector Gains

Mar 25 ▲ +1.5% Eli Lilly (LLY) Gains Amidst GLP-1 Optimism, Outperforms Sector

Mar 24 ▼ -0.8% Eli Lilly (LLY) Declines Amidst Sector Gains

Mar 23 ▲ +0.3% Eli Lilly (LLY) modestly up despite sector downturn

Mar 20 ▼ -1.2% LLY Down Slightly Amidst Sector Weakness

Mar 19 — -0.1% Eli Lilly (LLY) Slightly Down Amidst Sector Weakness

Mar 18 ▼ -1.3% LLY Down Amid Analyst Downgrade and Obesity Drug Competition

Mar 17 ▼ -6.1% Eli Lilly (LLY) Drops on Analyst Downgrade, Obesity Drug Concerns

Mar 16 ▲ +0.4% LLY edges higher on positive eczema drug trial data

Mar 13 ▲ +0.8% LLY Up Slightly Despite Sector Weakness; China Investment & GLP-1 Progress Boost Sentiment

Mar 12 ▼ -2.2% Eli Lilly (LLY) Down on Obesity Drug Impurity Concerns

Mar 11 ▼ -0.3% LLY Down Slightly Amidst Mixed Sector Performance

Mar 10 ▼ -0.7% LLY Down Slightly Amidst Sector Volatility

Mar 9 ▲ +1.6% LLY Up Slightly Amidst Sector Weakness and Mixed News

Mar 6 ▲ +0.7% LLY Up Slightly Amid Obesity Drug Developments

Mar 5 ▼ -2.2% Lilly (LLY) Down Amidst GLP-1 Market News

Mar 4 ▼ -0.2% Eli Lilly (LLY) dips slightly despite positive sector trends

Mar 3 ▼ -1.0% LLY Down Slightly Amidst Mixed Sentiment

Mar 2 ▼ -3.2% LLY Declines Amid Market Correction and Valuation Concerns

Feb 27 ▲ +2.8% Eli Lilly (LLY) Climbs on Positive Obesity Drug Market Sentiment

Feb 26 ▼ -0.7% Eli Lilly (LLY) dips slightly despite positive obesity drug market news

Feb 25 ▼ -1.2% LLY dips slightly amid sector gains, Ozempic price war

Feb 24 ▼ -1.6% Lilly (LLY) dips as Novo Nordisk plans GLP-1 price cuts.

Feb 23 ▲ +4.9% Eli Lilly (LLY) Surges Nearly 5% Amid Novo Nordisk Weight Loss Drug Concerns

Feb 20 ▼ -1.3% LLY dips slightly despite positive Crohn's data, Taltz-Zepbound combo results

Feb 19 ▲ +0.3% LLY Up Slightly on Positive Clinical Trial Data

Feb 18 ▼ -1.7% LLY Down Slightly Despite Positive Psoriasis-Obesity Trial Data

Financial Highlights

Income Statement

Revenue

$59.42B

Gross Profit

$49.34B

83.0% margin

Operating Income

$22.50B

37.9% margin

Net Income

$18.41B

31.0% margin

EPS (Diluted)

$20.44

Balance Sheet

Total Assets

$114.94B

Total Liabilities

$91.08B

Stockholders' Equity

$23.85B

Cash Flow

Operating Cash Flow

$16.06B

Investing Activities

-$10.09B

Net Cash Flow

$6.42B

Highly Regarded Analysis

Updated Apr 10, 2026 • Refreshes daily

Rating

Highly Regarded

Risk

Medium

Target

$1,224.59

Type

Standard

Executive Summary

Eli Lilly and Company is a global pharmaceutical company with a strong focus on cardio-metabolic health, oncology, neuroscience, and immunology. It is currently experiencing rapid growth driven by its blockbuster drugs Mounjaro and Zepbound, particularly in the obesity and diabetes markets. Analysts have a generally bullish outlook on the stock, citing its strong financial performance and robust pipeline. However, some caution is warranted due to a premium valuation and near-term technical weaknesses.

Bull Case

The bull case for Eli Lilly rests on its strong position in the rapidly growing obesity and diabetes markets, particularly with drugs like Mounjaro and Zepbound. The company's pipeline is also a key strength, with potential for new blockbuster drugs in the future. Expansion into global markets and scaling up manufacturing are expected to drive further revenue and margin growth.

Bear Case

The bear case highlights risks such as potential pricing pressure from governments and competition, especially from Novo Nordisk. There are also concerns about manufacturing stumbles and regulatory hurdles. A high debt level and premium valuation leave limited room for error. Disappointing results from key clinical trials or slower-than-expected uptake of new drugs could also negatively impact the stock.

Technical Outlook

The stock has demonstrated instances of rapid rallies in the past, indicating potential for future growth. However, some AI models indicate near-term technical weakness with the stock trading below key moving averages.

Fundamental Health

Eli Lilly's financial health is generally strong. Revenue and earnings have soared, with significant growth in operating income, net income, and EPS. The company's gross margin is high, and it has a strong return on assets and equity. However, debt has increased, and some valuation metrics, like the P/E ratio, are high.

Key Catalysts

Potential agreement with the U.S. government on tariffs
Positive trial results for new and existing drugs
Successful launches of new products, such as Foundayo (orforglipron)

Sources

tikr.com tipranks.com forbes.com trefis.com fullratio.com chartmill.com financecharts.com finviz.com simplywall.st tikr.com seekingalpha.com youtube.com public.com seekingalpha.com

This analysis was conducted by Highly Regarded's proprietary market analysis engine. It is not financial advice. Always do your own research and consult a financial advisor before making investment decisions.

Debt 3 min read